Healthcare & Life Sciences

Internet-Based CBT for Anxiety and Depression, Singapore, NCT07532551

NIH's ClinicalTrials.gov has registered a clinical trial (NCT07532551) in Singapore evaluating Internet-based Cognitive Behavioural Therapy (iCBT) for adults with mild-to-moderate anxiety and/or depression. The randomized controlled trial will compare guided iCBT to usual care (traditional CBT) to assess clinical effectiveness, cost-effectiveness, and acceptability. Participants will receive structured digital modules with therapist support. The trial is expected to complete in April 2026.

NECC Peer Support Observational Study for Neuroendocrine Cervical Cancer Patients

NIH registered an observational study (NCT07532954) titled 'The Impact Of A Patient Support Community On Patients With Neuroendocrine Cervical Cancer' on ClinicalTrials.gov. The study aims to learn about the effects of a participant support community on illness perception, emotional well-being, and feelings of isolation among participants with NECC using questionnaire-based interventions. No regulatory obligations or compliance requirements are imposed by this registry entry.

Kinesiophobia and Adhesive Capsulitis Observational Trial NCT07534527

NIH ClinicalTrials.gov registered observational study NCT07534527 investigating the relationship between kinesiophobia (fear of movement) and pain, range of motion, disability, and quality of life in patients with adhesive capsulitis (frozen shoulder). The study will involve physical examination and questionnaire-based assessment; no interventions are administered.

Holmium Laser Versus Conventional TURBT for Non-Muscle-Invasive Bladder Cancer: Randomized Controlled Trial, 100 Patients

NIH ClinicalTrials.gov registered a prospective randomized controlled trial (NCT07534631) comparing holmium laser en-bloc resection (HoLERBT) with conventional transurethral resection (cTURBT) for treatment of non-muscle-invasive bladder cancer. A total of 100 patients will be randomized 1:1. The primary outcome is quality of pathological specimen assessed by presence of detrusor muscle. Secondary outcomes include perioperative complications, operative time, obturator nerve reflex, bladder perforation, positive surgical margins, persistent disease at second-look TURBT, and recurrence rates at 3 and 12 months.

Therapeutic Touch and Acupressure on Depressive Symptoms (NCT07532512)

NIH ClinicalTrials.gov registered a new study (NCT07532512) investigating therapeutic touch and acupressure as interventions for mild-to-moderate depressive symptoms. The randomized controlled trial will enroll participants receiving either eight therapeutic touch sessions or eight acupressure sessions over four weeks. Acupressure points include Yintang (EX-HN3), Shenmen (HT7), and Neiguan (PC6).

CMS LEAD Model Creates Specialist ACO Participation Pathways

Benesch attorneys analyze CMS's Long-term Enhanced ACO Design (LEAD) Model, which creates new pathways for specialist physicians to participate in Medicare ACO programs beyond traditional fee-for-service arrangements. The model offers two participation options—Participant Provider (full ACO membership with shared savings/losses) or Preferred Provider (contract-based collaboration)—alongside flexible payment structures including Non-Primary Care Capitation and Advanced Payment Option.

CMS Finalizes Medicare Advantage and Part D 2027 Policies with 5.33% Growth Rate

CMS released a final rule and final rate notice for Medicare Advantage and Part D programs for contract year 2027. The final growth rate is 5.33%, up from the projected 4.97%, providing modest relief to MA plans. Key policy changes include removal of the Health Equity Index from Star Ratings, elimination of 11 of 12 proposed Star measure cuts, finalization of supplemental benefits debit-card provisions, and new marketing rules for agents and brokers. CMS also proposed risk model updates that would reduce MA risk scores by 3.32% in 2027, which stakeholders have challenged.

Healthcare Technology M&A Pulse Newsletter - April 2026

Bass, Berry & Sims PLC published its quarterly Healthcare Technology M&A Pulse Newsletter covering Q1 2026. The publication analyzes deal activity, regulatory developments, and trends at the intersection of healthcare and technology. This is a law firm newsletter providing market intelligence to clients and industry participants on digital health transactions.

Federal Circuit Affirms Noninfringement on Blood Culture Patents

The Federal Circuit affirmed judgment of noninfringement for Kurin, Inc. in a patent dispute with Magnolia Medical Technologies over blood culture contamination reduction devices. The court held that claim 1 of the '483 patent requires separate "seal member" and "vent" structures, and that "diverter" in the '001 patent is a means-plus-function term that Kurin's device does not satisfy.

Recent Disciplinary Actions by Quarter - Dentists and Dental Hygienists

The North Carolina State Board of Dental Examiners posted recent disciplinary actions taken against licensed dentists and dental hygienists. Actions include consent orders, reprimands, summary license suspensions, indefinite suspensions, conditional reinstatements, and probations spanning Q1 2026 through Q4 2024. Disciplinary orders remain public records accessible via the Board's license verification system.

Mississippi Dental Practice Act, Regulations, and Ethics Codes

The Mississippi State Board of Dental Examiners maintains an online resource page providing links to the Mississippi Dental Practice Act, regulations adopted by the board, public hearing guidelines, proposed amendments to board regulations, and ethics codes from the American Dental Association and American Dental Hygienists Association. The page serves as a central compliance resource for licensed dental professionals in Mississippi.

Public Disciplinary Orders Listed

Public Disciplinary Orders Listed

Measles Exposure Advisory at Mt Hood Community College, Gresham - April 13

Oregon Health Authority and Multnomah County public health officials have identified a new measles exposure location at Mt Hood Community College, Gresham Campus Academic Center Building 17. Individuals present at the location between 10 a.m. and 1:50 p.m. on Monday, April 13, 2026, may have been exposed. Officials are urging those potentially exposed to contact a healthcare provider to determine immunity status based on vaccination records, age, or laboratory evidence.

Quarterly Professional License Disciplinary Action Reports 2017-2026

The Alaska Division of Corporations, Business & Professional Licensing (CBPL) published its quarterly index of disciplinary actions for all professional licenses regulated by the division, covering 2017 through Q1 2026. The webpage provides links to PDF reports organized by quarter, with separate annual reports for 2017-2019. Individual disciplinary action documents are available via the Search Professional Licenses webpage, though upload of specific actions may take up to 60 days.

Oregon Medical Board Disciplinary Actions: 6 Licensee Actions Including Interim Orders

The Oregon Medical Board issued a Board Action Report documenting 6 licensee actions between November 16 and December 15, 2025. Actions include 2 Interim Stipulated Orders for emergency voluntary withdrawal from practice pending investigation (Crane, Sobotka), 3 Orders Terminating Consent Agreements for Re-Entry to Practice (Bouressa, Kameda-Smith, Zhang), and 1 Notice of Proposed Disciplinary Action (McEwen). Affected licensees include 5 physicians and 1 licensed acupuncturist.

Oregon Medical Board Disciplinary Actions December 2025 - January 2026

The Oregon Medical Board issued its disciplinary action report covering December 16, 2025 through January 15, 2026. The report summarizes various actions including non-disciplinary Consent Agreements for re-entry, Stipulated Orders imposing civil penalties up to $10,000, license revocations, and terminations of prior corrective action agreements. Actions involve physicians (MD), physician assistants (PA), and acupuncturists (LAc) licensed in Oregon.

Oregon Medical Board Actions, Jan 16 - Feb 15 2026

The Oregon Medical Board published its February 2026 Board Action Report covering actions from January 16 to February 15, 2026. The report documents multiple enforcement actions including Consent Agreements for Re-Entry to Practice, an Interim Stipulated Order for license inactivation pending investigation, and a Notice of Proposed Disciplinary Action. The Board maintains that interim actions are preliminary and do not constitute final disciplinary determinations.

Oregon Medical Board Actions, February-March 2026

The Oregon Medical Board published its action report summarizing regulatory activities between February 16, 2025, and March 15, 2026. The report covers Consent Agreements, Stipulated Orders, Emergency Suspensions, Final Orders, and other licensee actions. Three specific licensees are noted: Brigitte Diane Buehler, PA entered a non-disciplinary Consent Agreement for Re-Entry to Practice requiring 2,000 hours of supervised practice; Barbara Ayres Ball Trask, PA had a prior Consent Agreement terminated; and Sajad Zalzala, MD received a Notice of Proposed Disciplinary Action. The report indicates certain documents are available upon request through the Board's website or by contacting the Board directly.

Code of Virginia Administrative Process Act - 2025 Compilation

The Virginia General Assembly enacted the Administrative Process Act (Code of Virginia § 2.2-4000 et seq.), establishing the procedural framework for Virginia state agencies to adopt regulations and adjudicate cases. The Act codifies requirements for public participation in rulemaking, evidentiary hearings, hearing officer qualifications, and court review of agency decisions. The 2025 compilation includes guidance document provisions (§ 2.2-4002.1), fast-track rulemaking (§ 2.2-4012.1), and periodic review requirements (§ 2.2-4017).

License Suspension FAQ: Reinstatement Process for Virginia Healthcare Professionals

The Virginia Department of Health Professions published an FAQ explaining the mandatory license suspension process under Virginia Code § 54.1-2409 and the reinstatement process for healthcare professionals. Suspensions are triggered by felony convictions, license revocations/suspensions in other states, or surrenders in lieu of discipline in other states. The document outlines that reinstatement applicants must submit an application, cooperate with an investigation, and appear before the Board, which has 60 days to schedule a hearing after receiving a complete application.

Professional Medical Conduct Board Actions, 9,186 Records

The New York Office of Professional Medical Conduct publishes a dataset of 9,186 final disciplinary actions against medical professionals dating back to 1990. The data preview displays 50 recent entries including physician assistants, doctors of osteopathy, and medical doctors with effective dates ranging from February to March 2026. Actions include license numbers, license types (MD, DO, PA), and individual identifiers.

Two Men Charged With Fentanyl Manufacturing in NYC Building

DEA New York Division Special Agent in Charge Farhana Islam announced that two men have been charged with narcotics and firearms offenses for operating a fentanyl manufacturing plant in a residential building in New York City. The charges include narcotics manufacturing and distribution violations. This enforcement action was conducted in coordination with the Department of Justice.

Oregon Board of Pharmacy September 2025 Disciplinary Actions

The Oregon Board of Pharmacy published its September 2025 disciplinary action report covering 09/01/2025 through 09/30/2025. The report documents 8 enforcement actions against pharmacy licensees including pharmacists, pharmacy technicians, and pharmacy facilities. Cases listed include OMNICARE OF RP-0001227, JAZMIN ARELY T-0031430, AMANDAH KYM CPT-0010391, AMY HUONG MAI RPH-0009430, SEBASTIAN RISKIN RPH-0009699, WILLEM MARAIS RPH-0010399, and others. Orders are available for public review via the OBOP online licensure verification system under Board Orders.

October 2025 Disciplinary Action Report, 5 Licensees

The Oregon Board of Pharmacy published its monthly disciplinary action report for October 2025, listing five licensees against whom the Board has issued enforcement actions. The report contains licensee names, license numbers, and associated case numbers. Specific violations and penalties are not disclosed in this report; the full Board Orders are available through online verification or public records request.

Oregon Pharmacy Board Disciplinary Actions, January 2026

The Oregon Board of Pharmacy published its January 2026 disciplinary report listing 8 licensees subject to executed orders. Actions involve pharmacies and individual pharmacists including Drug Mart Pharmacy, UsPharma Ltd Co, RARX II LLC, and multiple registered pharmacists. The board's orders are public records available through the OBOP online licensure verification system.

Oregon Board of Pharmacy Disciplinary Actions, February 2026

The Oregon Board of Pharmacy issued disciplinary actions against seven licensees in February 2026, including pharmacists, pharmacy technicians, and pharmacy facilities. Affected parties include Mary Meng-Tai Lim (RPH-0008986), JAMS RX (W1-0004712), Corrina Wynn (CPT-0015898), Michael Sean Phelps (CPT-0009066), Lacey J Holsten (T-00320402), Collin Michael Hertzog (PI-0014916), and Navid Vahedi (RPH-0014571). Specific case numbers are listed, and public records requests may be submitted for additional information.

March 2026 Oregon Pharmacy Board Disciplinary Actions Report

The Oregon Board of Pharmacy issued disciplinary actions against multiple licensees during March 2026, including pharmacists, pharmacy technicians, and pharmacy facilities. Actions included licensees with case numbers ranging from 2020-0322 to 2026-0012. Some orders were issued as Oregon Board of Pharmacy v. proceedings, indicating formal disciplinary complaints. The report covers the period 03/01/2026 through 03/31/2026.

ACOD1 Gene Expression as Sepsis Mortality Predictor

NIH has registered a new observational clinical study (NCT07533994) on ClinicalTrials.gov evaluating ACOD1 gene expression in peripheral blood mononuclear cells as a prognostic biomarker for predicting sepsis mortality. The single-center study will enroll septic ICU patients and correlate ACOD1 expression with clinical severity scores and in-hospital mortality outcomes.

Tpex Subsets in Negative Tumor Draining Lymph Nodes for Predicting Efficacy of PD-1 Inhibitors in Esophageal Squamous Cell Carcinoma

NIH registered an observational study (NCT07533357) examining Tpex subsets in negative tumor draining lymph nodes as predictors of PD-1 inhibitor efficacy in advanced or recurrent esophageal squamous cell carcinoma. The study aims to determine whether high proportions of precursor exhausted T cells correlate with longer overall survival and whether Tpex has better predictive efficacy for treatment response than PD-L1 CPS.

Observational Trial of Deep Learning Model for Head and Neck Cancer Prognosis

NIH registered NCT07532928, an observational study developing a dynamic deep learning model using multimodal patient data to assess prognostic risk and recommend individualized adjuvant treatment for locally advanced head and neck squamous cell carcinoma. The model aims to assist clinicians in precision therapy decisions. The study is observational with an estimated enrollment of 500 participants, registered April 16, 2026.

Preoperative Topical Lidocaine Versus Intravenous Fentanyl for Intubation Stress Reduction

NIH registered clinical trial NCT07533643 comparing preoperative topical lidocaine versus intravenous fentanyl for reducing stress response during endotracheal intubation under general anesthesia. The trial will evaluate hemodynamics after intubation using combined topical airway anesthesia (nebulized, mouth rinsing and gargling) against low-dose IV fentanyl. No compliance obligations are created by this trial registration.

ML/AI Model Predicts Head and Neck Cancerous Lesion Risk

NIH registered ClinicalTrials.gov study NCT07532538, an observational multi-center trial to develop and validate a deep learning/AI-based clinical prediction model for head and neck cancerous lesion risk. The study targets hypopharyngeal cancer, laryngeal cancer, and general head and neck cancer. The trial is registered as an observational study without stated enrollment or completion dates.

Congenital Ptosis Surgery Visual Function and Psychological Conditions Prospective Cohort Study

NIH ClinicalTrials.gov registered NCT07534436, an observational prospective cohort study evaluating 6-month outcomes of Levator Resection combined with Fascial Sheath Suspension surgery in patients with congenital ptosis. The study will assess improvements in best-corrected visual acuity, stereopsis, and patient-reported quality of life through standardized ophthalmological examinations at baseline and 1, 3, and 6 months post-operation. Enrollment includes patients already scheduled for this combined surgical procedure as part of their regular medical care.

IPEX Observational Study on Pancreatic Exocrine Insufficiency in IPMN Patients

NIH registered the IPEX study (NCT07535125), a multicenter prospective observational cohort study evaluating pancreatic exocrine insufficiency (PEI) prevalence in patients with intraductal papillary mucinous neoplasms (IPMN) under surveillance. The study will assess whether PEI correlates with morphologic disease progression and whether it can serve as a functional marker complementary to imaging criteria in IPMN surveillance.

Guselkumab High-Dose vs Standard-Dose Study in Chinese Moderate-to-Severe Plaque Psoriasis

NIH registered a clinical trial (NCT07532486) on ClinicalTrials.gov evaluating the efficacy, safety, tolerability, and drug survival of guselkumab at high-dose and extended-interval regimens versus standard-dose in Chinese participants with moderate-to-severe plaque psoriasis. The interventional study compares two guselkumab dosing approaches. This is an administrative registration entry with no regulatory compliance obligations.

Trial Comparing Ultrasound-guided vs Arthroscopic Guided PRF Injection for TMJ Disc Displacement

NIH registered a clinical trial (NCT07535073) comparing ultrasound-guided versus arthroscopic guided platelet rich fibrin injection for temporomandibular joint disc displacement. The trial will evaluate pain reduction, improvement of mandibular function, and patient-reported outcomes. No regulatory obligations or compliance requirements are created by this study registration.

Piloting a Generative Artificial Intelligence Chatbot in a Mobile Weight Loss Program

NIH has registered a new clinical trial (NCT07534254) evaluating the feasibility of integrating a generative AI chatbot into a 12-week smartphone-based behavioral weight loss program for young adults. The study will compare standard program delivery (1-2 brief daily messages) against the same program enhanced with an AI chatbot offering additional behavior change support. Participants will be assessed on program feasibility, acceptability, engagement, and weight change outcomes.

Phase 4 Trial Comparing Symptom-Based vs. Full-Course Antibiotic Stop Rules in Children

NIH has registered a Phase 4 clinical trial (NCT07532941) at the Royal Children's Hospital evaluating whether oral antibiotics can be safely stopped when symptoms resolve in children who have completed IV antibiotic courses for cellulitis, UTI, LRTI, and lymphadenitis. The two-arm study compares symptom-triggered antibiotic cessation against traditional full-course completion. Participants complete daily symptom trackers with telehealth follow-up at symptom resolution, plus surveys at days 14, 28, and 180. The trial seeks to determine if abbreviated oral antibiotic courses are non-inferior to completing prescribed durations.

BOUGIE CAP Cohort Study, Esophageal Strictures

The NIH ClinicalTrials.gov registry has posted an observational cohort study (NCT07534800) evaluating the BougieCap™ device (Ovesco Endoscopy AG) for treating benign and short esophageal strictures. The study aims to assess the device's performance and short-term effectiveness on dysphagia. This is an informational registration entry for an ongoing clinical study.

Medical Digest Newsletter Subscription Page

The Alabama Board of Medical Examiners and Medical Licensure Commission maintains a Medical Digest newsletter for licensees containing disciplinary action lists and regulatory information. Licensees receive the digest automatically at their email address of record and may optionally subscribe to mail delivery. Non-licensees may request email subscriptions. The page archives past issues from 2022 through 2026 covering topics including license renewals, prescribing guidelines, CME requirements, and complaint procedures.

Alabama Medical Board Licensee Search Information

The Alabama Board of Medical Examiners provides information about its public licensee search tool, offering license verification including name, license number, status, issue/expiration dates, medical school, controlled substances certificates, collaborative practice information, and disciplinary actions. The search serves as primary source verification for credentialers and includes a downloadable daily-updated license roster CSV file. Confidential information including patient complaints, malpractice cases, investigations, full addresses, and birth dates is not provided.

Missouri Pharmacy Technician License Suspensions Pursuant to Section 324.010 RSMo

The Missouri Board of Pharmacy has published a list of pharmacy technician licenses suspended pursuant to Section 324.010, RSMo. The document includes names, license numbers, cities, and effective suspension dates for numerous individuals. Pharmacy technicians, healthcare providers, and pharmacies should verify current license status through the MO BOP before employment or dispensing decisions.

Pharmacy Technician Conditional Registration List

The Missouri Board of Pharmacy publishes its Conditional Registration List for pharmacy technicians. This list identifies individuals eligible for employment as pharmacy technicians under conditions printed on their registration certificates. The list includes names, cities, and end dates for conditional employment status. Pharmacists and employers should check this list alongside the Employment Disqualification List to verify authorization to work.

Pharmacy Technician Employment Disqualification List 2026

The Missouri Board of Pharmacy published its 2026 Pharmacy Technician Employment Disqualification List, containing approximately 100 individuals who are prohibited from employment as pharmacy technicians in Missouri. The list includes names, license numbers, action dates, action taken, and location information. Pharmacies and employers should consult this list and the Conditional Registration List to verify authorization before hiring pharmacy technicians.

40 Pharmacy Licensees Disciplined, April-June 2025

The California Board of Pharmacy published disciplinary actions against 40 licensees for the period April 1 through June 30, 2025. Outcomes include license revocations (with some stayed and placed on probation), voluntary surrenders, and one withdrawn accusation. Decisions were effective between April 2 and June 27, 2025.

41 Disciplinary Actions Against Pharmacy Professionals, July-September 2025

The California Board of Pharmacy published 41 disciplinary actions against pharmacy professionals for the period July 1 through September 30, 2025. Actions include 11 full revocations, 16 stayed revocations with probation periods ranging from one to five years, 5 voluntary surrenders, 2 application denials, 1 public reproval, and 1 withdrawn accusation. Decisions were effective between July 16 and September 24, 2025.

29 Pharmacy Licenses Revoked Probationed Surrendered

The California Board of Pharmacy published disciplinary actions for 29 licensees (pharmacists and pharmacy technicians) for the period October 1 through December 31, 2025. Actions included 14 outright revocations with ended practice rights, 11 stayed revocations with probation terms ranging from 35 months to 5 years, 2 voluntary surrenders, 3 application denials, and 1 dismissal. Decisions were effective between October 15 and December 19, 2025.

40+ Pharmacy Technician and Pharmacist License Revocations, Probations, and Surrenders, Q1 2026

The California Board of Pharmacy issued 40+ disciplinary decisions against licensed pharmacists and pharmacy technicians between January and March 2026. Outcomes include license revocations (with or without stayed revocation/probation), public reprovals, and voluntary surrenders. Cases span multiple cities across California including Los Angeles, Bakersfield, San Diego, and others.

Disciplinary Actions April-June 2026: Revocations, Probations, Surrenders

The California Board of Pharmacy published 15 disciplinary actions for Q2 2026 (April-June), affecting 13 personal licenses and 2 facility licenses. Decisions include absolute revocations, stayed revocations with probation, and voluntary surrenders. All decisions were effective April 1, 2026.

Brett Tyler Wahlgren M.D. Voluntary License Surrender

Dr. Brett Tyler Wahlgren, M.D./D.O. voluntarily surrendered his Alabama medical license (No. 43092) while under investigation by the Alabama State Board of Medical Examiners. The surrender, executed October 13, 2023, under Ala. Code § 34-24-361(g), constitutes a public record and will be reported to the National Practitioner Data Bank and Federation of State Medical Boards. The Board may summarily deny any reinstatement petition for two years, and reinstatement requires the physician to prove fitness to practice.